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ABSTRACT 
 The most common technique for analysis of drug substances is high performance 
liquid chromatography (HPLC) using a variable wavelength detector (UV). Cremophor® 
EL (ethoxylated castor oil, CrEL) is a non-ionic emulsifier that is used to assist in the 
solubilization of hydrophobic drugs such as the antineoplastic agent, paclitaxel. However, 
the molecular weight distribution of CrEL creates difficulties in the analysis of potency 
and related substances of hydrophobic drugs via UV detection. 
 Using a precipitation method, CrEL was selectively removed from the paclitaxel 
by pre-treating the injectable dosage form with mercuric chloride and analyzing the 
filtered extract by HPLC-UV.  The removal of CrEL from the injectable dosage form of 
paclitaxel by precipitation with mercuric chloride resulted in a solution that was suitable 
to quantitate active and related substances by HPLC-UV. The precipitate was then 
characterized by nuclear magnetic resonance, infrared spectrophotometry and x-ray 
diffraction to elucidate its mechanism of action. The combination of these analyses 
provided sufficient evidence that the complex formed between CrEL and mercuric 
chloride is from the coordination of the mercury atom to the ether oxygens present in the 
CrEL.  
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INTRODUCTION 
 For a drug to be marketed in the United States it must be effective, convenient, 
and most importantly, safe. Since parenterals are administered by injection, the quality of 
the finished drug product must be significantly higher than other dosage forms  
(Avis, et al., 1992). The standards set forth by the U.S. Food and Drug Administration 
(FDA) and United States Pharmacopoeia (USP), a private organization that works in 
collaboration with the FDA, ensure that the quality (identity, purity, quantity, and 
potency) of a drug product is as stated by the manufacturer (USP, 2005). Federal law 
requires manufactures, processors, and packagers of drugs to take a proactive approach to 
ensuring that their products are of the highest quality. The current Good Manufacturing 
Practices (cGMP), which are regulations promulgated by the FDA’s Code of Federal 
Regulations (CFR), provide the framework for companies to minimize or eliminate 
contamination and erroneous data. The FDA’s guidelines and standards for determining 
the quality of products generally include a series of methods that must be performed by 
an analytical laboratory to determine their chemical composition, both quantitatively and 
qualitatively.  
 In addition to cGMP, cost and convenience of administration are major concerns 
that affect the pharmaceutical industry. Analytical methods must be developed so that the 
drug products can be tested in their finished, ready-to-deliver, product form. However, 
some drug products must be manufactured using a two-vial system where one vial 
contains the active pharmaceutical ingredient and the other vial contains the solubilizer or 
excipient. The two vials are analyzed separately and once the products are released, the 
consumer mixes the vials immediately before use. This two-vial system is mandated 
2 
because there has not been a suitable technique or method developed that allows for the 
components to be accurately analyzed when combined or due to the instability of the drug 
product. Analytical laboratories must continually develop novel methods that allow for 
the quality of drug products to be determined in the presence of its excipients. 
 The primary goal of new drug formulations and reformulation of established drug 
products is to enhance bioavailability and effectiveness of the active pharmaceutical 
ingredient (API). The recent advances in novel drug formulations have substantially 
increased the amount of research and development required to bring a product to market. 
Costs are further escalated because of certain unseen challenges that are encountered 
when developing new analytical methods that determine the drug’s quality and stability.  
 The analytical tool that is used most extensively in determining the quality of 
drug products is high performance liquid chromatography (HPLC) (Snyder, 1997). Using 
HPLC methodology, the potency of compounds can be rapidly established by comparing 
a known reference standard with the analytes of interest. However, if peaks in a 
chromatogram attributed to the active or its related substances or degradents elute at the 
same retention times of the excipients or solubilizers inaccurate results will be obtained. 
Therefore, HPLC methods that accurately and specifically quantitate finished drug 
products by selectively removing interfering excipients with a sample preparation before 
the analyses are needed. Some techniques, like liquid-liquid extraction, preparative 
HPLC purification, and solid phase extraction (SPE) have been used to remove 
interfering excipients prior to HPLC analysis. Techniques like liquid-liquid extraction 
and SPE that depend on solvent selectivity can not be used for some excipients because 
they are soluble in such a diverse range of solvents. 
3 
 The major challenge in analyzing hydrophobic parenteral dosage forms by HPLC-
UV is the interference of the many peaks produced by the large molecular weight 
distribution of excipients such as CrEL. The retention times of the peaks due to 
solubilizing agents are sometimes the same as the related impurities and degradation 
products present in a drug product causing inaccurate results to be obtained. The analysis 
of newly derivitized formulations of hydrophobic drugs such as paclitaxel, for example, 
interfere with its excipient making the peaks due to the active and its related compounds 
very difficult to quantitate by HPLC-UV. 
 Paclitaxel (Taxol®, Bristol-Myers Squibb Company) is one drug product that has 
posed a challenge from an analytical standpoint. Paclitaxel is a potent natural product that 
is harvested from the bark of the Pacific Yew tree, Taxus brevifolia. Its chemical 
structure is depicted in Figure 1. 
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Figure 1. Molecular structure of paclitaxel. 
 
  Paclitaxel is an antineoplastic agent that is indicated for the treatment of non-
small cell lung cancer, refractory breast cancer, epithelial ovarian cancer, and potentially 
for multiple sclerosis and Alzheimer’s disease (Halford, 2005).  In 1977, the National 
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Cancer Institute (NCI) was faced with significant obstacles pertaining to the formulation 
of paclitaxel. The major challenge in developing its formulation was due to the absence 
of ionizable functional groups and a bulky fused ring system, which makes paclitaxel 
poorly soluble in aqueous media (less than 0.1µg/ml)(Suffness, 1995).  
 There are a variety of vehicles that have proven to be effective in 
transporting hydrophobic drugs within the human circulatory system. Mostly, the use of 
nonionic solubilizers has been applied by investigators in cancer chemotherapy because 
of their effectiveness. One of the non-aqueous formulations proposed and accepted by 
NCI for paclitaxel was a formulation consisting of the emulsifier/solubilizer, 
polyethylene glycol triricinoleate 35 (Cremophor® EL, BASF) and ethanol (Suffness, 
1995). CrEL is an FDA approved amphiphilic polymer that is used as a solubilizer for the 
delivery of a variety of hydrophobic parenteral drugs. It is a viscous liquid that is formed 
by the reaction of ethylene oxide with castor oil at a molar ratio of 35:1 (BASF, 1998). A 
major component (80%) of CrEL consists of a hydrophobic glycerol-polyethylene glycol 
ricinoleate which is shown in Figure 2 (BASF, 1998). 
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Figure 2. Molecular structure of CrEL. Σ(x,y,z) = 30-33 
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The remaining 20% of CrEL contains 7% polyethylene glycol, 10% glycerol 
polyoxyethylene, and 3% non reacted castor oil (Meyer, et al., 2002). Nonionic surfactant 
molecules, such as CrEL, have no formal ionic charge. Its polarity arises from the 
combined effects of the many ether linkages joined to the nonpolar moiety  
(Yalkowsky, 1999). CrEL, like most surface active agents, contain flexible nonpolar 
alkyl chains that are oriented toward the hydrophobic core where the drug resides. The 
polar region forms the hydrophilic corona that hydrogen bonds with the water molecules. 
A schematic of this arrangement of CrEL molecules forming a micelle around a 
paclitaxel molecule is illustrated in Figure 3. The threshold concentration above which 
micelles form, that is, the critical micelle concentration (CMC) for CrEL in an aqueous 
solution was previously determined by cryogenic temperature transmission electron 
microscopy (cryo-TEM) to be 97-102 µg/mL (Szebeni, et al., 2001). 
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Figure 3. A schematic of the micellar arrangement of CrEL surrounding a paclitaxel 
molecule. (Note: Ethylene oxides in parenthesis are 10-11 units in length.) 
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 One of the unique properties of CrEL that BASF chemists discovered is that it is 
soluble in the presence of many electrolytes. Most all salts and acids, provided their 
concentrations are not too excessive, will not cause CrEL to precipitate out of solution 
(BASF, 1999). However, mercuric chloride and compounds that contain phenolic 
hydroxyl groups, such as resorcinol, tannin, and phenol may cause precipitation at certain 
concentrations (BASF, 1999). Based on these unique properties, a method for CrEL-
containing drug products can be developed that allows CrEL to be removed by 
precipitation before the analysis of parenteral drug products by HPLC-UV. The pre-
treatment of an injectable hydrophobic drug product containing CrEL with mercuric 
chloride will allow for the analysis to proceed with negligible interference from the 
CrEL.   
 When CrEL is subjected to a saturated ethanolic solution of mercuric chloride, a 
dense, white precipitate is formed. When a majority of the CrEL is precipitated out of a 
solution in this manner, mercuric chloride may be selective enough to complex with and 
remove the interfering excipient from the injectable dosage form. Once CrEL is removed, 
the drug product can be analyzed by HPLC-UV with no interference from the CrEL.   
 This novel precipitimetric approach to analyzing paclitaxel in a one vial system 
can also be applied to other hydrophobic drugs containing CrEL. In order to apply this 
precipitimetric method to other CrEL-containing finished drug products, it is critical to 
investigate mercuric chloride’s mechanism of action. If mercury specifically complexes 
certain functional groups present in both the solubilizer and the API, the method would 
be rendered less suitable. The precipitation reaction was studied using a variety of 
8 
techniques including qualitative analysis, Fourier transform infrared spectrophotometry 
(FTIR), 1H and 13C nuclear magnetic resonance (NMR), and X-ray diffraction. 
 A rapid qualitative analysis was performed to explore the potential sites where the 
reaction might take place. In the qualitative analysis study, compounds that represented 
key functional groups of CrEL were reacted with ethanolic mercuric chloride to 
determine what part of the CrEL molecule is interacting with the mercuric chloride. 
Certain functional groups that were candidates for the mercuric chloride reaction were 
alcohols, ethers, and olefins. 
 The most valuable instrumental technique employed to elucidate the mechanism 
of interaction was 1H-NMR and 13C-NMR. The goal of the NMR studies was to support 
the theory of mercuric chloride complexing with the ether units present in CrEL. Special 
attention was given to the changes that took place in the chemical shifts when CrEL 
reacted with mercuric chloride.  
 Supporting data was collected using techniques in FTIR and X-ray diffraction. If 
the complex is formed between the ethers and the mercury ion, then changes in the 
degrees of motion for the ether bonds should be prevalent in the IR spectra. Furthermore, 
an X-ray diffraction pattern of an isolated crystal of the mercury-complexed CrEL would 
be sound evidence to support the proposed theory of this precipitation reaction. 
 Since the discovery of paclitaxel’s use as a chemotherapy drug, there have been a 
variety of studies pertaining to its purification, preparation and application. Most of the 
recent published data addresses the application and the resulting clinical effects of the 
intravenously administered paclitaxel and/or CrEL (Ghassempour, et al., 2003, 
Gelderblom, et al., 2002, Meyer, et al., 2001, Kunkel, et al., 1999, Gelderblom, et al., 
9 
1999, Huizing, et al., 1998, and Sparreboom, et al., 1996). One method that particularly 
addresses the chromatographic analysis of paclitaxel and CrEL was developed by Lillian 
Shao and David Locke (Shao and Locke, 1997). The method they developed utilizes 
micellar electrokinetic capillary chromatography to separate paclitaxel and related 
taxanes (Appendix B) in the bulk drug as well as its injectable dosage form. 
  More recently, Ciutaru, et al. developed and validated a HPLC method that 
evaluates paclitaxel’s related taxanes in its finished injectable form (Ciutaru, et al., 2003).  
Ciutaru, et al. obtained chromatographic data that showed baseline resolution of the 
related substances in the presence of CrEL. It was noted that there was difficultly in the 
separation of related taxane peaks in the sample that contained CrEL. The method was 
optimized and validated so that the peaks of the CrEL did not interfere with the related 
taxanes.  
 The methods proposed by Shao and Locke and Ciutaru, et al. may be suitable for 
analyzing the pure natural product, paclitaxel, in the presence of CrEL.  However, the 
peaks in the chromatographic analysis due to derivitized formulations of paclitaxel 
interfere with the peaks of CrEL, making quantitation of the active and related 
compounds difficult to analyze. In HPLC analysis, as illustrated here, it is paramount to 
analyze finished products without interference from the excipient matrix. 
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EXPERIMENTAL 
Equipment 
 1H and 13C nuclear magnetic resonance (NMR) spectra were acquired on a Bruker 
Avance DRX400 multinuclear spectrometer. All the compounds used in the NMR 
analysis were dissolved and read in d6-acetone. The spectra were acquired and processed 
with XWINN-NMR® software.  
 Infrared (IR) absorption spectra were obtained with a Mattson Genesis Series 
Fourier transform infrared (FTIR) spectrophotometer and then processed with Winnfirst® 
software.  
 X-ray crystallographic data was obtained on a Nonius Kappa CCD diffractometer 
and a Siemens D500 X-ray powder diffraction instrument. All measurements were 
carried out at 23 ˚C using monochromated Cu (Kα ) radiation (λ=1.54178Å). The data 
was processed with Maxus Solution® software. 
 The high performance liquid chromatography (HPLC) components used were a 
Hewlett-Packard 1100 autosampler, Hitachi L-7100 quaternary gradient pump, and a 
Waters 2487 dual wavelength absorbance detector. An auxiliary HPLC system was used 
that consisted of the same components as listed above except a Waters 717Plus 
Autosampler was used. The column used throughout was a Phenomenex Curosil, 250mm 
x 4.6 mm, with a 5 µm particle size bonded with pentafluorophenyl (PFP) groups. The 
column was maintained at ambient temperature. Separations were achieved using a 
mixture of acetonitrile and water at 40% acetonitrile for mobile phase A and 70% 
acetonitrile for mobile phase B. A gradient elution, flowing at 1.0 mL/min (except where 
noted), was performed from 0 to 25 minutes, 90% mobile phase A, from 25 minutes to 60 
11 
minutes, 100% mobile phase B, and from 60.1 minutes to 70 minutes 90% mobile phase 
A. These steps in the gradient, which significantly increased the runtime were critical in 
eluting the excipient, CrEL and other retained impurities from the precipitation reaction. 
Analytes were detected at 228 nm. The injection volume was 10µL. All chromatographic 
data was acquired and processed with Waters Millennium® 4.0.  
 
Chemical Information 
 See Appendix A for the list of chemicals and manufacturers used for each type of 
analysis/study performed. 
 
Procedure 
     Sample Preparations 
 The stock solution of paclitaxel was prepared in a similar manner to the 
formulation of the injectable dosage form that is currently marketed (PDR, 2005). 
Paclitaxel was dissolved in a 50% v/v solution of CrEL in ethanol at a concentration of 
25 mg/mL. Working standard solution (1) was prepared by diluting the stock solution in 
ethanol to obtain a final concentration of 0.5 mg/mL, which is approximately the final 
concentration (0.3 mg/mL to 1.2 mg/mL) of the drug when being administered by 
intravenous infusion. Working solution (2) was prepared at the same concentration as (1) 
except using an intermediate solution containing saturated mercuric chloride in ethanol, 
centrifuging and immediately filtering the supernatant with a Gelman Acrodisc 0.45 µm 
borosilicate glass hydrophilic polypropylene (GHP) filter before diluting to the same 
concentration (0.5 mg/mL). The pellet remaining in the centrifuge tube was transferred to 
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a Buchner funnel and washed with ethanol then dried over silica gel, under vacuum, for 
three days.  
 Polyethylene glycol 400 (PEG 400) was dissolved in ethanol to furnish a 50% v/v 
solution. To a tube containing 5 mL of this solution, 10 mL of saturated ethanolic 
mercuric chloride was added and mixed vigorously. To a tube containing 5 mL of 
triglyme, 10 mL of saturated ethanolic mercuric chloride was added and mixed 
vigorously. The resulting precipitates from each reaction were washed and dried like the 
CrEL precipitate.  
     Rate of Precipitation Reaction 
 To estimate the rate of the mercury- CrEL reaction, a preliminary time study was 
performed. A 50:50 mixture of saturated ethanolic mercuric chloride and CrEL was 
vortexed for 30 seconds and immediately centrifuged at 5000 rpm for ten minutes. The 
supernatant was decanted into a test tube, capped, and placed at ambient laboratory 
conditions for 48 hours. No further precipitation was evident. Based on these findings, 
the reaction of mercuric chloride in ethanol with CrEL was determined to be immediate. 
     Preparations for NMR Analysis 
 For the 1H-NMR analysis, the dried CrEL precipitate was weighed into d6-acetone 
to obtain a concentration of 20 mg/mL. A preparation of the unreacted CrEL was 
prepared similarly. The 13C-NMR analyses of the same components were obtained in the 
same solvent but at a concentration of 50 mg/mL. The same experiments were run with 
PEG 400 at the same concentrations as CrEL. The d6-acetone peak was used for 
calibration (2.04 ppm for 1H-NMR spectra and 29.94 ppm for 13C-NMR spectra). The  
13 
1H-NMR integral regions were relative to the calibrated acetone peak that was arbitrarily 
set at 1.00.  
     Preparations for FTIR Analysis 
 Ten milligrams of the CrEL precipitant was triturated intimately with 4 drops of 
mineral oil (nujol) in a mortar. The mixture was suspended between two sodium chloride 
plates and the spectrum was obtained in a blank subtracted background. Ten milligrams 
of the triglyme precipitant was prepared similarly. The spectrum of the unreacted CrEL 
and triglyme were also obtained under the same conditions as the precipitant.  
     Preparations for X-ray Analysis 
 Using a microscope, a representative crystal was selected from the dried CrEL 
precipitant and mounted on a glass fiber with epoxy cement. The data was collected by 
ω-2θ scans. 
     Preparations for HPLC Analysis                                                                                                                
 A mixture of thirteen related taxanes was commercially purchased from Hauser 
Chemical Research Company. The list of the taxanes and their structures is located in 
Appendix B. The taxanes in this mixture represent the most commonly found related 
substances present when analyzing the bulk, natural drug product, paclitaxel. For the 
recovery study, working solution (3) was prepared with paclitaxel at 0.5 mg/mL and 
spiked with the thirteen taxane mixture at 1.0% using the intermediate ethanolic mercuric 
chloride solution described above. A control of paclitaxel at 0.5 mg/mL, working 
standard (4), was spiked with the thirteen taxane mixture in absence of CrEL. A blank 
preparation of 50% v/v CrEL in ethanol and saturated ethanolic mercuric chloride was 
made in a centrifuge tube. The resulting mixture was centrifuged at 5000 rpm for 10 min. 
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A portion of the supernatant was decanted into a GHP syringe filter, filtered, and diluted 
to the same concentration as the final working standard solutions.   
 
RESULTS AND DISCUSSION 
 Over the past several years, there have been a multitude of studies published that 
evaluate the complexation of metal ions with ethers and etheral polymers (Maunu, et al., 
1987, Varshney, et al., 1991, Doxsee, et al., 1993, Costero, et al., 1998, Shou, et al., 
1999). A majority of these reports, however, have been of crown ether complexes and 
other non-polymer, well-characterized molecules containing ethers. Nonetheless, their 
results provide insight into the use of metal ions to complex organic compounds. 
 The etheral polymer, CrEL that is used in the preparation of the hydrophobic 
drug, paclitaxel has to be selectively removed so valid quantitative and qualitative 
chromatographic data for the finished product can be obtained. A unique property of 
CrEL that will allow for its removal from the parenteral formulation of paclitaxel, is by 
selectively precipitating with metal ions. 
Precipitimetric Analysis 
 BASF, the manufacturer of CrEL, reports that CrEL is unstable in solutions 
containing mercuric chloride in addition to phenolic hydroxyl compounds (BASF, 1997). 
A series of experiments was performed to determine the most effective agent for 
removing CrEL from a solution by precipitation. A solution of CrEL was prepared at a 
50% v/v dilution in ethanol to mimic the solubilizing concentration in finished dosage 
forms of paclitaxel. The metal ions in addition to mercury that were mixed with CrEL are 
listed in Table 1 (manufacturers are listed in Appendix A). When saturated solutions of 
15 
the metal ions listed in Table 1 were added to the 50% v/v ethanolic CrEL solution, most 
yielded no visible precipitate. If a complex did form with these metals, the metal-
complex was soluble and was not further investigated due to the lack of a precipitate. 
BASF also reported that some organic substances, such as resorcinol and phenol, may 
cause precipitation. Experimentation with these phenolic hydroxyls yielded no observable 
result. The use of organic substances as precipitating agents was also not pursued further.  
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Table 1. Compounds that were mixed with 50% v/v CrEL in ethanol to investigate 
alternative precipitating agents. 
 
Compound Insoluble precipitate with CrEL 
Mercuric chloride Yes 
Mercuric iodide No 
Mercuric bromide Yes (slight) 
Barium chloride No 
Mercuric acetate Yes (slight) 
Resorcinol No 
Phenol No 
Ferric chloride No 
Lanthanum chloride No 
Cobalt chloride No 
Copper chloride No 
Zinc chloride No 
Nickel chloride No 
Silver chloride No 
Stannous chloride No 
Magnesium chloride No 
Lead acetate No 
Lithium chloride No 
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 The basis of selectivity for metal ions in open chain ligands such as CrEL has 
previously been investigated from a thermodynamic and geometric standpoint (Hancock, 
1992). In addition to favorable entropy effects, and to a much lesser degree, enthalpy 
effects, the stability of the CrEL-metal complex in ethanol is strongly related to the size 
of the metal ion being chelated. Typically, metals such as lead(II), mercury(II), and 
barium(II) that have an ionic radius greater than 1.0 Å, will strongly bind to CrEL where 
as metals that have ionic radii smaller than 1.0 Å will not. For the metal to form an 
insoluble complex, the metal ion must also maintain its bonds with the cation so as to 
produce a neutral ethanol-insoluble polymer. Based on the hard/soft acid base principle, 
mercury(II) is a soft acid that strongly binds chloride ions where as lead(II), a borderline 
hard acid and barium(II) a hard acid do not maintain their bonds to chloride ions during 
complexation (MacKay, et al., 2002). This theory supports the reason why the only metal 
salt that successfully yielded a sufficient quantity of precipitated CrEL was mercuric 
chloride. 
  The interaction of mercury and CrEL was initially thought to take place at the 
carbon – carbon double bond with the π electrons acting as the nucleophile, the mercury 
as the electrophile, and the chloride ions possibly as the leaving group thus forming a 
stable mercurinium compound, as illustrated in Figure 4 (Cotton, et al., 1988 ). 
 
C C R'R
Hg+
R'R + HgCl2
HH
etoh
 
Figure 4. A schematic of an olefin complex, forming a mercurinium compound. 
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Another experiment was performed with short alkenes to investigate the possibility of the 
interaction illustrated in Figure 4. 1-Octene and 2-heptene were used as representative 
olefins and mixed with a saturated ethanolic solution of mercuric chloride. No visible 
precipitate was immediately obtained. The solutions were covered with a pin-punctured 
piece of foil and left for about 14 days. White crystals formed at the bottom of each of the 
reaction tubes. Using a microscope, a representative crystal was selected from the  
1-octene reaction tube and mounted for an X-ray diffraction pattern. It was determined 
that the crystals that were in the tube were of the recrystallized mercuric chloride, thus 
proving this theory incorrect. Based on the result obtained with the 1-octene solution, the 
2-heptene solution was not analyzed by X-ray diffraction. From this experiment it can be 
inferred that the reaction appears to be taking place with the ether linkages and not the 
olefin as initially thought.  
 To determine which moiety of the CrEL structure was interacting with the 
mercury, a rapid qualitative analysis using compounds that represent the major functional 
groups was tested. The compounds that simulate the particular regions of CrEL, cis-3-
hexen-1-ol, castor oil, glycerol ethoxylate, and polyethylene glycol (PEG 400) were used. 
There structures are depicted in Figure 5. They were each individually reacted with 
saturated ethanolic mercuric chloride solution. Of these four compounds, PEG 400 and 
glycerol ethoxylate were the compounds that, when mixed with mercuric chloride formed 
a white, insoluble salt.  
 
 
 
19 
 
 
OH  
Cis-3-hexen-1-ol 
 
HO
HO
O
 
Castor oil (~90% cis-ricenoleic acid) 
 
CH2(OCH2CH2)nOH
CH2(OCH2CH2)nOH
CH(OCH2CH2)nOH
 
Glycerol ethoxylate, n=6-7 
 
 
Polyethylene Glycol (MW 400), n≈9 
Figure 5. Molecular structures of chemicals used for simulating the functional groups 
present in CrEL. 
 
 
H(OCH2CH2)nOH
20 
 Other compounds that were investigated contained linear chains of ethers, like 
diglyme and tryglyme. Diglyme (Figure 6) proved unsuccessful in producing an insoluble 
precipitate where as triglyme, with one more ethylene unit, successfully complexed with 
mercuric chloride to form a white precipitate.  
 
O
O
O + HgCl2 NO  PPT
 
Figure 6. Reaction of diglyme and mercuric chloride. 
 
 Perhaps the reason diglyme was unsuccessful at complexing a mercury (II) ion is 
because this cation typically forms four-coordinate tetrahedral structures in monomers 
where diglyme has only three coordinating ether oxygens (Helm, et al., 2002). 
Furthermore, diglyme may not be large enough to geometrically allow the oxygens to 
chelate the mercury atom. Triglyme, with its all-ether structure, is very similar to crown 
ethers in that they dissolve many inorganic salts by chelating the cation (Figure 7) 
(Glymes, 2005). The white, solid complex that triglyme formed with mercury was 
insoluble in ethanol, much like that seen in CrEL and PEG 400.  
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Figure 7. Reaction of triglyme and mercuric chloride to form an insoluble complex. 
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 With mercuric chloride being the only salt that furnished a precipitate with CrEL 
in ethanol, the method was further optimized to separate the solid CrEL from the 
solution. Based on membrane selection guides, hydrophobic drug literature, and previous 
projects run using these solvents and compounds, a GHP syringe filter was selected for 
this method (Williams, et al., 2001). No filter study was performed on the method 
developed here. The precipitate that was formed from reacting mercuric chloride with 
CrEL was immediate when performed in ethanol and was easily removed from the 
solution by filtration.  
NMR Analysis 
 Nuclear magnetic resonance spectroscopy was utilized to map the changes that 
took place in the carbon-hydrogen framework when CrEL complexed with mercury. The 
information derived from both the 1H-NMR and 13C-NMR spectra proved to be 
extraordinarily useful for determining the change in the chemical environment when 
mercury is complexed with CrEL. Even though a molecule the size and complexity of 
CrEL is difficult to fully interpret by NMR spectroscopy, many structural features can 
still be recognized.  
 The greatest amount of information that was gained from the NMR experiments 
was from the change in chemical shifts when the CrEL was complexed with mercuric 
chloride. When a spectrum of the pure polymer was obtained and compared to the 
mercury-complexed CrEL, the chemical (magnetic) environments of certain nuclei were 
effected.  For instance, Figure 8 shows the overlay of the 1H-NMR spectra of the raw 
polyethoxylated castor oil (CrEL) and the mercury-complexed CrEL. In regards to 
chemical shift changes present in these spectra, the most notable variation is the 
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absorption of the hydrogens adjacent to the electronegative ether oxygens. In the CrEL 
spectrum, the largest ether absorption is at 3.58 ppm and when mercury is complexed 
with CrEL, it shifts downfield to an absorption of 3.66 ppm. From this 0.1 ppm shift, it is 
evident that there is a removal of electron density surrounding the nuclei of the ether 
protons when mercury is present. Similar shifting patterns in 1H-NMR were seen in 
previous spectroscopic studies focusing on the polyether coordination of alkali metal 
cations (Popović, 2000 and Isab, 1995). Another obvious difference in the two spectra is 
the absorption at approximately 2.84 ppm (Figure 8). When the CrEL was complexed 
with the mercuric chloride, filtered and dried, it caused the broad peak at 2.84 ppm to 
split into two distinct sharper peaks. The presence of residual water in raw, liquid CrEL 
could potentially be masking the –OH groups present in the CrEL. To correctly identify 
these absorptions as protons contributed from a functional hydroxyl group, another 
experiment was performed. The NMR tubes containing CrEL and the mercury-
complexed CrEL that were dissolved in d6-acetone, 50 µL of deuterated water (D20) was 
added, mixed and the NMR spectra obtained (see Figure 9 and 10). The broad peak that 
was initially observed in CrEL is absent after the D2O was added. As seen in Figure 10, 
the two peaks that were present at about 2.84 ppm are absent after the addition of D2O 
indicating that the exchange of similar protons found in the raw CrEL was evident. The 
protons were replaced with deuterium as illustrated below, thus proving that these were 
 –OH protons. 
R-O-H + D-O-D → R-O-D + D-O-H 
The absorptions for CrEL and CrEL-Hg complex were also integrated relative to the 
solvent, d6-acetone. The difference in integration between the two compounds is 
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negligible. See Appendix C for the spectra containing the integrated absorptions. No 
changes in chemical shifts of alkene protons (5.40 ppm), methylene protons of the 
ricenoleic fatty acids (1.20 ppm) and glycerol protons (4.85 ppm and 4.15 ppm) were 
observed. In conclusion, the 1H-NMR data suggests that mercuric chloride is being 
complexed by the ether oxygens present in CrEL. 
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Figure 8. Overlay of CrEL (bottom) and Hg-complexed CrEL (top) 1H-NMR spectra. 
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2.83 ppm
 
Figure 9. Overlay of CrEL(top) and CrEL-deuterated water (bottom) 1H-NMR spectra. 
 
 
 
 
 
27 
 
 
 
 
 
 
-O-H
2.85 ppm
2.81 ppm
 
Figure 10. Overlay of Hg-complexed CrEL (top) and Hg-complexed CrEL-deuterated 
water 1H-NMR spectra (bottom). 
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The 13C-NMR spectra of CrEL and the Hg-CrEL complex provided further 
support of the results from the 1H-NMR studies. The 13C-NMR spectra furnished results 
that were unexpected at first in the region where carbons bound to oxygen absorb. The 
chemical shifts of carbons single-bonded to oxygen generally absorb between 80 ppm 
and 40 ppm. Figures 11-13 illustrate the specific absorptions of CrEL and the Hg-CrEL 
complex. In Figure 11, the region where the alkane carbons absorb (40 ppm to 20 ppm) is 
shown. As expected, there is no noticeable shifting that takes place in this region.         
Figure 12 illustrates the region where there is significant shifting when mercury is 
complexed with CrEL. In the area between 80 ppm and 60 ppm there are absorptions that 
arise from the carbons bearing oxygens in CrEL. The chemical shifts are upfield in the 
spectrum of the Hg-complexed CrEL, due to a shielding effect on the carbons adjacent to 
the ether oxygens and the esters present. The carbonyl carbons of CrEL, which absorb at 
approximately 174 ppm, do not show any effect when mercury is complexed as seen in 
Figure 13. The results obtained in the 13C-NMR study further supports that the ether 
oxygens present in CrEL are complexing with the mercuric chloride. 
 A survey of the recent literature pertaining to 13C-NMR shifts in mercury ether 
complexes was performed to investigate these shifts that are in contrast (opposite 
shifting) to those found in the 1H-NMR spectra. One study by Gray and Duffey included 
a spectroscopic study that addressed how metallocrown ethers bind heavy metal cations 
such as Hg2+ (Gray and Duffey, 1995). The 13C-NMR data was obtained for a penta-ether 
molybdenum compound that was complexed with mercuric chloride. When the mercury 
atom complexed with the ethers of the molybdenum compound, as further-evidenced by 
X-ray diffraction studies, the chemical shift of the carbons flanked by the ether oxygens 
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were strongly shielded and required a higher applied field to bring them into resonance. 
This upfield shift of the ether absorptions in the molybdenum complex supports the 13C-
NMR shifting of CrEL illustrated in Figure 12. Thus, this change in the chemical 
(magnetic) environment of the C-O region shows support that the CrEL is complexing 
with the mercury ion. The lack of changes in the alkene region between 150 ppm to 100 
ppm of CrEL and Hg-complexed CrEL proves that the olefin present in CrEL is not 
involved in the complexation reaction. 
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CrEL-Hg Complex
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Figure 11. Overlay from 40 ppm to 20 ppm of CrEL (top) and  
CrEL-Hg complex (bottom) 13C-NMR spectra. 
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Figure 12. Overlay from 80 ppm to 60 ppm of CrEL (top) and  
CrEL-Hg complex (bottom) 13C-NMR spectra. 
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Figure 13. Overlay from 176 ppm to 170 ppm of CrEL and Hg-complexed CrEL 
 13C-NMR spectra. 
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 To further support the theory that the mercury is coordinating with the 
electronegative oxygens present in CrEL, another NMR spectroscopy experiment was 
performed on PEG 400, a compound that reacts with mercuric chloride in a similar 
fashion to CrEL. The spectra in Figure 14 are of PEG 400 and PEG 400 complexed with 
mercuric chloride, prepared in a similar manner as CrEL. The full scale spectra can be 
found in Appendix C. Figure 14 shows a significant shift of the ethylene protons when 
complexed with the mercury. The major absorption for PEG 400 at 3.57 ppm has shifted 
to 3.66 ppm when complexed with mercury. This deshielding effect corresponds to the 
results seen in the CrEL shifts (0.1 ppm shift). The peak also exhibits more individual 
peaks over a broader region as previously observed with the CrEL-Hg complex. 
 The data obtained from the 13C-NMR spectra for PEG 400 was analogous to the 
data obtained for the CrEL. Figure 15 shows an overlay of the PEG 400 and the Hg-
complexed PEG 400 13C-NMR spectra.  There is an upfield shift in the ether absorption 
region from 71.31 ppm in the PEG 400 to 70.83 ppm in the Hg-complexed PEG 400. 
This -0.5 ppm change in the absorption is indicative of a shielding effect due to the 
complexation of mercuric chloride, which is analogous to the results obtained in the 
studies performed with CrEL. 
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Figure 14. Overlay of PEG 400 and Hg-complexed PEG400 
 1H-NMR spectra. 
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Figure 15. Overlay of PEG 400 and Hg-complexed PEG 400  
13C-NMR spectra. 
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FTIR Analysis  
 The interactions between metal ions, like divalent mercury, and polymers have 
been shown to be weak in nature (Caykara, et al., 2004). Although binding forces such as 
coordination bonds, hydrogen bonds, and charge-transfer interaction are generally weak, 
they act cooperatively to affect the molecular environment during complex formation 
(Caykara, et al., 2004). To aide in understanding these possible interactions and changes 
in the molecular environment when the polymer CrEL is complexed with mercuric 
chloride, techniques in Fourier transform infrared spectrophotometry (FTIR) were 
employed. FTIR was used to investigate the vibrational changes in certain functional 
groups present in CrEL and the Hg-complexed CrEL. The particular functional groups of 
interest were the alkene, ester, and ether absorption regions.  
 Figure 16 shows the FTIR spectra obtained from 4000 cm-1 to 500 cm-1 for the 
pure polymer CrEL and Figure 17 shows the solid Hg-compexed CrEL. The pure CrEL 
and the complexed solid were triturated with mineral oil (Nujol), suspended between two 
sodium chloride plates and read using the infrared spectrophotometer. The absorption 
bands at 1375 cm-1 and 1460 cm-1 in addition to the broad absorption at 2900 cm-1 are 
partly contributable to the Nujol that was used to suspend the samples. In comparison of 
the two CrEL-containing spectra found in Figure 16 and Figure 17, the most notable 
difference between the two spectra is the hydroxyl region (3600 cm-1) due to residual 
water, the ether region (1100 cm-1), and the ester region (1730cm-1).  The absence of the 
–OH stretch in Figure 17 is due to drying the CrEL-mercury complex in a vacuum over 
silica gel. The residual moisture present in the raw, liquid CrEL was not able to be 
removed by drying in a vacuum over silica gel. The C-O bending due to the ether 
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linkages at 1100 cm-1 is substantially reduced when complexed with mercuric chloride. 
The ester peak found at 1730 cm-1 also shows a significant decrease is absorption when 
complexed with mercuric chloride.  No absorptions were observed for the alkene 
absorption regions (3020-3100 cm-1 and 1650-1670 cm-1). 
 To support the observed changes in the IR spectra that were obtained with the 
CrEL preparations, the same study was performed with triglyme, as illustrated in Figure 
18 and Figure 19. The same effect was observed in the ether region (1100 cm-1) for 
triglyme when it was complexed with the mercuric chloride as illustrated in Figure 19. 
From the FTIR data that was obtained for the CrEL it is apparent that etheral oxygens 
present in the molecule have a significant effect on the complexation with the cation, 
mercury. This theory is supported by the similar results obtained for the ether, triglyme.   
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    Figure 16. IR spectrum of CrEL. 
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Figure 17. IR spectrum of Hg-complexed CrEL. 
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Figure 18. IR spectrum of triglyme. 
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Figure 19. IR spectrum of Hg-complexed triglyme. 
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X-ray Analysis  
 An X-ray diffraction study was performed to aid in the elucidation of the 
mechanism of action for the precipitation of the CrEL. For single-crystal diffractometry, 
it is essential to obtain a crystal that is of sufficient size (0.1-0.3 mm), shape (no physical 
distortion) and uniform in its internal structure (Stout and Jensen, 1989). The selected 
crystal must be pure at the atomic, ionic, or molecular level so as to provide meaningful 
X-ray diffraction data. Therefore, the technique utilized to grow crystals from the liquid 
phase becomes paramount. One of the preferred methods, and the one selected here, is to 
grow crystals from a saturated solution that is allowed to slowly evaporate.  
 The first experiment performed attempted to show that the mercury atom was 
complexing with the olefinic region of CrEL and then precipitating out of solution. To 
simulate this reaction, 1-octene was mixed in a flat-bottom glass tube with an excess of a 
saturated ethanolic solution of mercuric chloride then covered with a punctured piece of 
aluminum foil. After the ethanol evaporated, a single white crystal was isolated using a 
microscope, mounted on a glass fiber and placed in the gonimeter head. The data points 
that were collected showed that the crystal was recrystallized mercuric chloride and that 
no reaction resulting in crystallization with the olefin present in 1-octene took place.   
 Another X-ray study was performed on the precipitate obtained from the reaction 
of CrEL with the ethanolic solution of mercuric chloride. Many attempts to isolate a 
satisfactory crystal of the CrEL complex were tried using different solvents (dimethyl 
sulfoxide, acetonitrile, ethanol, acetone, methanol, and dimethyl formamide) as well as 
different divalent metal atoms (mercury, copper, cobalt, and zinc). The only substantial 
crystals that were obtained were from the expected CrEL in ethanolic mercuric chloride.  
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Other solvent evaporations (methanol and dimethyl formamide) with mercuric chloride 
furnished microcrystals that were unsuitable for analysis.  
 The diffractogram in Figure 20 is of the large crystal-like solid obtained from the 
precipitation reaction of CrEL and ethanolic mercuric chloride. Since CrEL is not a pure 
and distinct compound that can produce sizable, uniform crystals when complexed with 
mercuric chloride, the quality of the diffraction pattern detailed in Figure 20 is expected. 
From this diffraction pattern (Figure 20) and its tabulated data (Appendix D), it is evident 
that the precipitate obtained is both amorphous and crystalline in nature due to the 
fluctuating baseline and the sharp peaks respectively. To draw conclusive evidence from 
this diffraction pattern, however, a significant amount of further research is needed to 
develop an effective recrystallization technique for an isolated CrEL molecule so as to 
properly identify the peaks present and thus, its true crystal structure.  
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Figure 20. Diffractogram of Hg-complexed CrEL. 
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HPLC-UV Analysis 
 Reverse-phase high performance liquid chromatography with ultra-violet 
detection was utilized to physically separate and detect the chemical compounds present 
in the parenteral formulation of paclitaxel. The extracts obtained from the bark and the 
needles of the Pacific Yew tree contain a variety of taxanes in addition to paclitaxel, 
which sometimes appear at low levels in the finished drug product. Over the last two 
decades, a significant amount of research has been conducted on the separation of these 
taxanes using HPLC. Until recently, bonded phases containing cyano-, phenyl-, and 
octadecyl- groups where used (Shao and Locke, 1997). A new type of column with a PFP 
bonded phase has been designed specifically for the taxanes which is remarkably 
efficient. PFP phases are unique in their selectivity toward compounds containing 
aromatic rings and other electron-rich groups as compared to alkyl-modified silicas. 
Thus, the PFP bonded phase was selected for its ability to retain analytes with functional 
groups that possess π electron systems as well as other electron-rich functional groups. 
Nevertheless, a method must be developed that allows not only the separation of the 
taxanes but the excipient from the taxanes as well. It is unfortunate that the excipient 
(CrEL) that is required to make the drug soluble, has almost the identical absorption 
spectrum (λmax ≈ 230 nm) as paclitaxel (Shao and Locke, 1997). This may cause 
significant interference with coeluting peaks that are contributable to the drug product. 
   Dilutions of CrEL with ethanol were first prepared and injected onto the PFP 
column and adjustments to the gradient and the injection volume were made so as to 
optimize the chromatography. The precipitation reaction was applied to a 50% v/v 
ethanolic solution of CrEL and injected onto the column. The resulting chromatograms 
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are overlayed in Figure 21. It is evident from Figure 21 that the removal of CrEL is 
highly effective by the mercuric chloride precipitimetric method. The many peaks 
between 17 min and 50 min caused by the large molecular weight distribution of CrEL 
are removed. The ramp in the gradient of the mobile phase allowed for compounds 
retained from the mercuric chloride precipitation reaction to be removed from the column 
as is evidenced at 65 min in Figure 21. 
 Initial HPLC testing was performed on the paclitaxel raw material that was 
prepared at 50 mg/mL in 50% v/v ethanolic CrEL and diluted with water to have a 
working concentration of 1.0 µg/mL. Paclitaxel was diluted to 1.0 µg/mL to establish the 
sensitivity of the instrument. The dilutions were initially made in water so as to prevent 
the peak splitting that sometimes happens when organic liquids are injected into an 
aqueous/organic phase system. It was observed during the analysis that the complexation 
was not immediate and complete. Over a period of a week, the quantity of the precipitate 
continued to increase in the filtered aliquot placed in the autosampler vial. When the 
dilutions of stock solutions were carried out in ethanol instead of water, the reaction was 
immediate and complete as evidenced by the absence of further precipitation after the 
initial precipitate was centrifuged and filtered. As a result, all dilutions of stock solutions 
were exclusively prepared with ethanol and not water. No peak-splitting was observed in 
this method. 
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Figure 21. Chromatographic overlay of a 1.0% v/v ethanolic solution of CrEL (bottom) 
and the solution after precipitation and filtration (top). 
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 To demonstrate the broad range in which the solubilizer elutes, 1.0 mL of a  
0.6 mg/mL paclitaxel solution in ethanol was spiked into 2.0ml of a 50% v/v CrEL 
ethanolic solution. The chromatogram in Figure 22 illustrates this very large distribution 
of CrEL. For drug substances that exhibit a greater hydrophobicity than paclitaxel and 
use additional CrEL in their parental formulation when analyzing by HPLC will be an 
issue. 
 In order to determine if the precipitation reaction influences the drug product, an 
experiment was performed with paclitaxel (25 mg/mL in 50% v/v ethanolic CrEL) 
diluted to 0.5 mg/mL. In Figure 23, the top chromatogram is of the 0.5 mg/mL paclitaxel 
solution and the bottom chromatogram is paclitaxel treated with saturated ethanolic 
mercuric chloride and diluted to 0.5 mg/mL. The chromatograms illustrated in Figure 24 
were acquired on the auxiliary system described in the experimental section with the flow 
set at 1.5 mL/min. A majority of the CrEL was removed with the mercuric chloride 
precipitation reaction and paclitaxel was not affected, as evidenced by the minor change 
in the area counts of its peak (percent recovered: 95.4%). 
  To illustrate the selectivity of mercuric chloride for CrEL, Figure 24 shows a 
chromatographic overlay of two preparations of the related substances. The bottom 
chromatogram is a preparation of paclitaxel prepared at 0.5 mg/mL in ethanol and spiked 
with a commercially purchased mixture of 13 taxanes at 0.1% of the 25 mg/mL paclitaxel 
solution. The top chromatogram is of a preparation made at the same concentrations as 
the control with CrEL present (10 µL/mL). A substitution of saturated ethanolic mercuric 
chloride solution was used during an intermediate dilution step and filtered as stated in 
the procedure. System suitability was established with five replicate injections of the 
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control solution with a percent-relative standard deviation (%RSD) at less than 3.0% for 
all 14 components.  
 The elution order of the taxanes is broadly related to the molecular size and 
increasing hydrophobicity. The retention time of the taxanes increase as the number of 
acetylated hydroxyl groups and xylosyl groups are added to the taxane ring, (Shao and 
Locke, 1997). The selectivity for the retention of taxanes is contributed by the π-π 
interactions of the fluorines on the stationary phase with the carbonyl oxygens, the 
principal electron-rich groups in the taxanes. In Table 2, the retention times and area 
counts are listed for each of the related substances (taxanes) present in the control 
solution illustrated in the bottom chromatogram in Figure 24. Table 3 lists the retention 
times, area counts, and percent recovery of the related substances after precipitating CrEL 
from the solution prepared at the same concentration as the control (top chromatogram in 
Figure 24). Since the same concentrations were used for both preps, the percent-recovery 
values were obtained by taking the ratio of the area counts of sample to the area counts of 
control and multiplying by 100%. From the percent-recovery results illustrated in  
Table 3, it is evident that the complexation of mercuric chloride does not interfere with 
paclitaxel or its related substances. This allows for the peaks of interest in the drug 
product to be accurately determined and quantitated.  
 The preparations illustrated in Figure 24 contained some impurities that were not 
identified. There is one peak at 6.0 minutes in the top chromatogram that is an artifact of 
a compound retained on the system and is diminishingly present in replicate injections of 
the solution. Fortunately, this peak does not interfere with the related taxanes. There are 
smaller extraneous peaks present in both chromatograms that may be due to either the 
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degradation of paclitaxel, additional taxanes present in the commercially purchased 
mixture or impurities in the CrEL. The literature suggests that certain grades of CrEL 
contain a sufficient amount of water to cause degradation of the paclitaxel (Shao and 
Locke, 1997). The additional peaks seen in the chromatographic analysis of the paclitaxel 
used in this method may be attributed to the CrEL used in this analysis. The CrEL is of 
pharmaceutical grade. However, the container has been exposed to atmospheric moisture 
during the last year and was not further purified. The moisture value for CrEL determined 
by Karl Fisher titrimetric methods was 2.5%.  
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Figure 22. Chromatogram of paclitaxel (0.3mg/mL) dissolved in 50%CrEL in ethanol. 
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Figure 23. Chromatographic overlay of paclitaxel (0.5 mg/mL) in CrEL and paclitaxel 
with CrEL removed by mercuric chloride precipitation. 
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Figure 24. Chromatogram of precipitated and filtered paclitaxel (0.5 mg/mL) in ethanolic 
CrEL solution spiked with related substances mixture (0.1%) overlayed with a control 
solution prepared at the same concentration with no CrEL. 
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Table 2. Retention times, and area counts for control preparation of paclitaxel and its 
related substances. 
 
Number/Name RT Control (min) Area Control 
1. 10-Deacetylbaccatin III 4.89 10340 
2. Baccatin III 7.24 8382 
3. 7-Xylosyl-10-deacetyl-taxol B 7.99 8710 
4. Taxinine M  8.33 9905 
5. 7-Xylosyl-10-deacetyl-taxol 9.17 5547 
6. Degradation peak unknown  10.31 4861 
7. 7-Xylosyl-10-deacetyl-taxol C 10.66 9180 
8. 7-Xylosyl-taxol 11.34 12244 
9. 10-deacetyl-taxol 13.68 7814 
10. Cephalomannine (taxol B) 13.99 20912 
11. 7-Epi-10-deacetyl-taxol 14.66 14422 
12. Taxol 15.44 9755687 
13. Taxol C 16.61 6860 
14. 7-Epi-taxol 19.05 26675 
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Table 3. Retention times, area counts, and percent-recovery after the precipitation of 
CrEL from paclitaxel and its related substances. 
 
Number/Name RT Sample (min) Area Sample %Recovery 
1. 10-Deacetylbaccatin III 4.90 11520 111 
2. Baccatin III 7.23 7679 92 
3. 7-Xylosyl-10-deacetyl-
taxol B 8.01 10092 116 
4. Taxinine M 8.31 9359 94 
5. 7-Xylosyl-10-deacetyl-
taxol 9.14 6136 111 
6. Degradation peak 
unknown  10.37 4352 90 
7. 7-Xylosyl-10-deacetyl-
taxol C 10.67 9198 100 
8. 7-Xylosyl-taxol 11.35 14292 117 
9. 10-Deacetyl-taxol 13.71 8820 113 
10. Cephalomannine 
(taxol B) 14.05 26271 126 
11. 7-Epi-10-deacetyl-
taxol 14.75 16160 112 
12. Taxol 15.52 10753090 110 
13. Taxol C 16.68 6806 99 
14. 7-Epi-taxol 19.19 28873 108 
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CONCLUSION 
 For drugs that are poorly soluble in water and are most efficacious by parenteral 
administration, solubilizers such as CrEL are a necessary excipient. Furthermore, the 
need for quantitatively and qualitatively determining these finished products will always 
be mandated by the FDA. The sample treatment demonstrated here can be applied to 
hydrophobic drugs in their finished product form that would otherwise suffer from 
specificity issues due to CrEL.  
 The additional analysis performed on CrEL and mercury-complexed CrEL 
encompassed the use of NMR, FTIR and X-ray to aide in determining the mechanism of 
action. The data obtained from these experiments support the theory that CrEL is 
selectively removed from a solution by divalent mercury binding to the polyether moiety 
of the CrEL. Furthermore, the evidence collected from the instrumental analyses 
presented here is supported by the literature referenced herein. 
 The goal of this work was to establish a sensitive and selective reversed-phase 
HPLC method for the determination of a hydrophobic drug with CrEL removed by a 
precipitimetric method. As an application of this method, Taxol® for injection 
concentrate was prepared as the drug product because of its well known structure and 
many related substances. The use of mercuric chloride to remove the solubilizer, CrEL, 
from Taxol® for injection concentrate is adequate for the proposed objective.  The 
recovery results for the HPLC analysis of the 13 related taxanes demonstrate the theory 
that mercury is selective enough to remove CrEL without removing the active, paclitaxel 
and its related substances.  
  
57 
REFERENCES 
 
Anvarhusein, Isab A.,  Perzanowski, Herman P., 1H, 13C, and 199Hg NMR Studies of the 
  -NHCS- Containing Ligands with Mercuric Halides., Polyhedron. 1995 (15-14) 
 2397-2401. 
 
Avis, Kenneth E., Lieberman, Herbert A., and Lachman, Leon., Pharmaceutical Dosage 
 Forms: Parenteral Medications, Second Edition., New York: Marcel Dekker, Inc. 
 1992 (1). 
 
BASF Aktiengesellschaft, Cremophor EL Technical Bulletin, Marketing Feinchemie, 
 Ludwigshafen, Germany., November 1998. 
 
Caykara, T., Inam, R., Öztürk, Z., Determination of the Complex Formation Constants 
 for Some Water-soluble Polymers with Trivalent Metal Ions by Differential Pulse 
 Polarography., Colloid Polymer Science. 2004 (282) 1282-1285. 
 
Ciutaru, Dana, Badea, Irinel, Lazar, Lelia, Nicolescu, Daniela, and Tudose, Aurel., A 
 HPLC Validated Assay of Paclitaxel’s Related Impurities in Pharmaceutical 
 Forms Containing Cremophor EL., Journal of Pharmaceutical and Biomedical 
 Analysis. 2004 (34) 493-499. 
 
Costero, A.M., Andreu, C., Monrabal, E., Tortajada, A., Ochando, L.E., Amigo, J.M., 
 Bis-cyclic Crown Ether Derived from Biphenyl. Different Behavior in Complexing 
 Hg(SCN)2 and Hg(CN)2., Supramolecular Chemistry. 1998 (9) 211-219. 
 
Cotton, F.A., Wilkinson, G., Advanced Inorganic Chemistry, Fifth Edition., New York: 
 John Wiley and Sons, 1988. 
 
Doxsee, K.M., Keegan, D.S., Wierman, H.R., Hagadorn, J.R., Arimura, M., 
 Complexation-Mediated Crystallization., Pure & Applied Chemistry. 1993 (65-3) 
 429-434. 
 
Duplay, David, Physicians’ Desk Reference, 59thEdition., Montvale, New Jersey: 
 Thomson PDR Publishers. 2005. 
 
Gelderblom, Hans, Verweij, Jaap, Brouwer, Eric, Pillay, Marrimuthoo, DeBruijn, Peter, 
 Nooter, Kees, Stoter, Gerrit, Sparreboom, Alex, Disposition of [G-3H]Paclitaxel 
 and Cremophor® EL, in a Patient with Severely Impaired Renal Function., Drug 
 Metabolism and Disposition.1999 (27(11)) 1300-1305. 
 
Gelderblom, Hans, Verweij, Jaap, van Zomeren, Desiree M., Buijs, Dirk, Ouwens, 
 Nooter, Kees, Stoter, Gerrit, Stoter, Sparreboom, Alex, Influence of 
 Cremophor® EL on the Bioavailability of Intraperitoneal Paclitaxel., Clinical 
 Cancer Research. 2002 (8) 1237-1241. 
 
58 
Ghassempour, Alireza, Nabid, Reza Nabid, Talebi, Mohammad, Entezami, Ali Akbar, 
 Comparison of Pyrolysis Mass Spectrometry with High Performance Liquid 
 Chromatography for the Analysis of Cremophor® EL in Drugs and Serum., 
 Talanta. 2003 (59) 435-441. 
 
Gray, Gary M., Duffey, Christina H., Size-Selective Reactions of cis-
 Mo(CO)4{Ph2P(CH2CH2 O)nCH2CH2PPh2-P,P’} (n=4,5) Metallacrown Ethers 
 with Mercury (II) Salts. Crystal Structure of cis- 
 Mo(CO)4{µ-Ph2P(CH2CH2O)5CH2CH2PPh2-P,P’,O,O’,O’’, O’’’, O’’’’}·HgCl2, 
 an Unusual Bimetallic Complex Containing a Molecular Cleft., 
 Organometallics. 1995 (14) 245-250. 
 
Halford, Bethany., Potential New Use for Paclitaxel. Chemical and Engineering News. 
 January 3, 2005, 9.  
 
Hancock, Robert D., Chelate Ring Size and Metal Ion Selection. Journal of Chemical 
 Education. 1992 (69(8)) 615-621. 
 
Helm, Monte L., Combs, Charles M., VanDerveer, Donald G., Grant, Gregory J., 
 Homoleptic Group 12 Metal Complexes of Macrocyclic Thioethers: the Crystal 
 Structures of Bis(1,4,7-trithiacyclodecane)M(II) perchlorate: M(II) = Zinc(II), 
 Cadmium(II), Mercury(II)., Inorganica Chemica Acta. 2002 (338) 182-188. 
 
Huizing, M.T., Rosing, H., Koopmans, F.P., Beijnen, J.H., Influence of Cremophor® EL 
 on the Quantification of Paclitaxel in Plasma Using High Performance Liquid 
 Chromatography with Solid-Phase Extraction as Sample Pretreatment., Journal 
 of Chromatography B. 1998 (709) 161-165. 
 
Kunkel, M., Meyer, T., Böhler, J., Keller, E., Frahm, A.W., Titrimetric Determination of 
 Cremophor® EL in Aqueous Solutions and Biofluids. Part 2: Ruggedness of the 
 Method with Respect to Biofluids., Journal of Pharmaceutical and Biomedical 
 Analysis. 1999 (21) 911-922.  
 
MacKay, K.M., MacKay, R.A., Henderson, W., Introduction to Modern Inorganic 
 Chemistry, Sixth Edition, Nelson Thornes Ltd., United Kingdom. 2002. 
 
Maunu, S.L., Lindburg, J.J., Structural and Electrical Studies on Poly(ethylene oxide) 
 Complexed with Inorganic Salts., Polymer Bulletin. 1987 (17) 545-549. 
 
Meyer,T., Waidelich, D., Frahm, A.W., Polyoxyethylene-∆9,11-didehydrostearate and 
 Glycerol-polyoxyethylene-∆9,11-didehydrostearate: Two New Components of the 
 Non-ionic Emulsifier Cremophor® EL., Journal of Pharmaceutical and 
 Biomedical Analysis. 2002 (30) 263-271. 
 
 
59 
Meyer, Th., Böhler, J., Frahm, A.W., Determination of Cremophor® EL in Plasma After 
 Sample Preparation with Solid Phase Extraction and Plasma Protein 
 Precipitation., Journal of Pharmaceutical and Biomedical Analysis. 2001 (24) 
 495-506. 
 
Popović, Zora, Pavolvić, Gordana, Matković-Čalogović, Dubravka, Soldin, Želika, Rajić, 
 Maša, Vikić-Topić, Dražen, Kovaĉek, Damir, Mercury(II) complexes of 
 Heterocyclic thiones. Part 1. Preparation of 1:2 Complexes of Mercury(II) 
 halides and Pseudohalides with 3,4,5,6-Tetrahydropyrimidine-2-thione. X-ray, 
 Thermal Analysis and NMR Studies., Inorganica Acta. 2000 (306) 142-152. 
 
Shao, Lillian Kuangjing and Locke, David C., Determination of Paclitaxel and Related 
 Taxanes in Bulk Drug and Injectable Dosage Forms by Reversed Phase Liquid 
 Chromatography., Analytical Chemistry. 1997 (69) 2008-2016. 
 
Shao, Lillian Kuangjing and Locke, David C., Separation of Paclitaxel and Related 
 Taxanes by Micellar Electrokinetic Capillary Chromatography., Analytical 
 Chemistry.1998 (70) 897-906. 
 
Shou, W.Z., Browner, R.F., Evaluation of Crown Ether Complexation for Elemental 
 Electrospray Mass Spectrometry., Analytical Chemistry. 1999 (71) 3365-3373. 
 
Snyder, Lloyd R., High Performance Liquid Chromatography, Advances and 
 Prospectives., CS. Horvath Ed., New York: Academic Press. 1980. 
 
Sparreboom, Alex, van Tellingen, Olaf, Huizing, Manon T., Nooijen, Willem J., Beijnen, 
 Jos H., Determination of Polyoxyethyleneglycerol triricinoleate 35  
 (Cremophor®  EL) in Plasma by Pre-Column derivatization and Reversed-Phase 
 High Performance Liquid Chromatography., Journal of Chromatography B. 1996 
 (681) 355-362. 
 
Stout, G.H., Jensen, L.H., X-ray Structure Determination, A Practical Guide, Second 
 Edition, New York: John Wiley and Sons, 1989. 
 
Suffness, Matthew., Taxol Science and Applications., CRC press., 1995. 
 
Szebeni, Janos, Alving, Carl R., Savay, Sandor, Barenholz, Yechezkel, Priev, Aba, 
 Danino, Dganit, Talmon, Yeshayahu, Formation of Complement-Activating 
 Particles in Aqueous Solutions of Taxol: Possible Role in Hypersensitivity 
 Reactions., International Immunopharmacology 1. 2001 721-735.  
 
The U.S. Pharmacopoeia, 28th ed., U.S. Pharmacopeial Convention: Rockville, MD. 
 2005. 
 
 
60 
Varshney, A., Gray, G.M., cis-Mo(CO)4{Ph2P(CH2CH2O)nCH2CH2PPh2} (n=3-5) 
 Metallocrown Ethers. The X-ray Crystal Structure of cis-
 Mo(CO)4{Ph2P(CH2CH2O)nCH2CH2PPh2-P,P’}., Inorganic Chemistry.1991 
 (30) 1748. 
 
Williams, R.O., Sykora, M.A., Mahaguna, V., Method to Recover a Lipophilic Drug 
 From Hydroxypropyl Methylcellulose Matrix Tablets., AAPS PharmSciTech. 2001 
 (2(2)) Article 8. 
 
www.glymes.com/description.php  
 
Yalkowsky, Samuel H., Solubility and Solubilization in Aqueous Media., American 
 Chemical Society and Oxford University Press., 1999. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
APPENDIX  
Appendix A. Reagents used for each study. 
Type of analysis/ 
study 
reagent Manufacturer/ supplier 
Precipitation Mercuric chloride 
Mercuric iodide 
Mercuric bromide 
Barium chloride 
Mercuric acetate 
Polyethylene glycol (mw 400) 
Diglyme (diethylene glycol 
dimethyl ether) 
Triglyme (triethylene glycol 
dimethyl ether) 
Glycerol ethoxylate 
Cis-3-hexene-1-ol 
Resorcinol 
Cremophor® EL 
Ethanol 
Water 
Cobalt chloride 
Zinc chloride 
Nickel chloride 
Silver chloride 
Stannous chloride 
Magnesium chloride 
Lead acetate 
Lithium chloride 
Ferric chloride 
Lanthanum chloride 
Castor oil 
Phenol 
Aldrich 
Aldrich 
Aldrich 
Aldrich 
Aldrich 
Mallinckrodt 
Aldrich 
 
Aldrich 
 
Aldrich 
Aldrich 
Aldrich 
BASF 
Aaper 
Milli-Q Ultra Pure 
Aldrich 
Aldrich 
Aldrich 
Aldrich 
Aldrich 
Aldrich 
Fisher 
Fisher 
Fisher 
Fisher 
Fisher 
Aldrich 
Solubility  Dimethyl sulfoxide 
Carbon tetrachloride 
Chloroform 
Dichloromethane 
Acetonitrile 
Ethanol 
Acetone 
Mercuric chloride 
Cremophor® EL 
Methanol 
Burdick and Jackson 
Aldrich 
Mallinckrodt 
Aldrich 
Burdick and Jackson 
Aaper 
Mallinckrodt 
Aldrich 
BASF 
Fisher 
62 
NMR Cremophor® EL 
Mercuric chloride 
Ethanol 
Deuterated acetone 
Deuterated water 
BASF 
Aldrich 
Aaper 
Aldrich 
Aldrich 
IR Mineral oil (Nujol) 
Mercuric chloride 
Cremophor® EL 
Ethanol 
Sigma 
Aldrich 
BASF 
Aaper 
X-ray Cremophor® EL 
Mercuric chloride 
Ethanol 
Methanol 
Isopropanol 
Dimethyl formamide 
Cobalt chloride 
Zinc chloride 
Nickel chloride 
Silver chloride 
Lead acetate 
BASF 
Aldrich 
Aaper 
Fisher 
Fisher 
Burdick and Jackson 
Aldrich 
Aldrich 
Aldrich 
Aldrich 
Fisher 
HPLC Paclitaxel 
Acetonitrile 
Cremophor® EL 
Ethanol 
Water 
Mercuric chloride 
13-Taxanes mixture 
AAI Pharma 
Burdick and Jackson 
BASF 
Aaper 
Milli-Q Ultra Pure 
Aldrich 
Hauser Chemical 
Research 
  
 
 
 
 
 
 
 
Appendix B. Molecular structures of paclitaxel and related substances (taxanes). 
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Appendix C. Additional 1H-NMR and 13C-NMR spectra. 
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Fullscale, integrated 1H-NMR spectrum of CrEL. 
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Fullscale, integrated 1H-NMR spectrum of CrEL-Hg complex. 
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13C-NMR spectrum of CrEL. 
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13C-NMR spectrum of CrEL-Hg complex. 
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13C-NMR spectrum of PEG 400. 
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13C-NMR spectrum of PEG 400-Hg complex. 
 
 
 
 
 
Appendix D. X-ray tabulated data for Figure 20. 
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ID 
2-
Theta D(A) Peak %P Area A% 
1 6.30 14.02 201 10.9 50 8.2 
2 11.50 7.69 1847 100.1 598 100.0 
3 13.69 6.47 1364 73.8 392 64.1 
4 14.80 5.98 683 37.0 182 30.4 
5 18.74 4.73 216 11.7 45 7.4 
6 23.05 3.86 291 15.8 66 10.9 
7 24.21 3.67 714 38.7 242 40.4 
8 27.45 3.25 367 19.9 107 17.8 
9 29.75 3.00 283 15.3 56 9.3 
10 31.95 2.80 893 48.3 470 78.7 
11 35.60 2.51 580 31.4 265 44.3 
12 37.98 2.37 177 9.6 43 7.3 
13 39.21 2.30 243 13.2 66 11.0 
 
 
 
